Summary
To assess whether intrarenal dopamine synthesis could contribute to the renal response to ANP in essential hypertension, the effects of α-human ANP influsion (50 ng·min−1·kg−1 b.w. for 30 min) on the urinary excretion of dopamine and sodium, urine flow rate and arterial pressure were evaluated in 7 patients with mild-moderate essential hypertension before (control period) and during DOPA-decarboxylase inhibition with carbidopa (carbidopa period).
In the control period, urinary dopamine excretion was 400 pg·min−1 in baseline conditions and 340 pg·min−1 during ANP infusion. Carbidopa significantly decreased urinary dopamine excretion both before (210 pg·min−1) and during ANP (99 pg·min−1). In contrast, carbidopa did not affect sodium excretion (control from 184 to 460 μEq·min−1; carbidopa period from 140 to 390 μEq·min−1) or urine flow rate (control from 5.35 to 11.21 ml·min−1; carbidopa period from 4.29 to 11.54 ml·min−1).
Arterial pressure fell significantly during ANP infusion in both periods, and no significant difference was observed between the two study days, i.e. in the absence of and during carbidopa administration.
We conclude that DOPA-decarboxylase inhibition does not influence the diuretic and natriuretic response to α-human ANP infusion in patients with essential hypertension.
Similar content being viewed by others
References
De Bold AJ, Borenstein HB, Veress AT, Sonnenberg H (1981) A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci 28: 89–94
Cody RJ (1989) Pathophysiology of atrial natriuretic peptide in hypertension. In: Brenner BM, Stein JH (eds) Atrial natriuretic peptides. Livingstone, New York, pp 264
Hollister AS, Inagami T (1991) Atrial natriuretic factor and hypertension. Am J Hypertens 4: 850–865
Iannettone CM, Strazzulla G, Fabbri G, Pazza E, Valenza P, De Feo ML, Franchi F (1991) Effetti della somministrazione acuta di peptide atriale natriuretico su alcuni meccanismi di regolazione della diuresi e della natriuresi nell'iperteso essenziale. Ann Ital Med Int 6: 273–283
Ishii M, Sugimoto T, Matsuoka H, Hirata Y, Ishimitsu T, Fukui K, Sugimoto T, Kangawa K, Matsuo H (1986) The hemodynamic, renal and endocrine effects of α-h atrial natriuretic polypeptide (α-hANP) in normotensive persons and patients with essential hypertension. J Hypertension 4: S542-S545
Richards AM, Nicholls MG, Espiner EA, Ikram H, Yandle TG, Joyce SL, Cullens MM (1985) Effects of α-h atrial natriuretic peptide in essential hypertension. Hypertension 7: 812–817
Goldberg LI (1972) Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev 24: 1–29
Levinson PD, Goldstein DS, Munson PJ, Gill JR, Keiser HR (1985) Endocrine, renal and haemodynamic responses to graded dopamine infusions in normal men. J Clin Endocrinol Metab 60: 821–826
Marin-Grez M, Briggs JP, Schnermann J (1985) Dopamine receptor antagonists inhibit the natriuretic response to atrial natriuretic factors (ANF). Life Sci 36: 2171–2176
Petterson A, Hedner J, Hedner T (1986) The diuretic effect of atrial natriuretic peptide (ANP) is dependent on dopamine activation. Acta Physiol Scand 126: 619–621
Webb RL, Della Puca R, Manniello J, Robson RD, Zimmerman MB, Ghai RD (1986) Dopaminergic mediation of the diuretic and natriuretic effects of ANF in the rat. Life Sci 38, 2319–2327
Murphy MB, Bass AS, Goldberg LI (1988) Renal effects of atrial natriuretic factor are independent of dopamine receptors. Am J Physiol 255: F494-F499
Freeston S, MacDonald TM, Jeffrey RF, Brown J, Lee MR (1989) The renal effects of atrial natriuretic peptide in man are not attenuated by (+)-sulpiride. Br J Clin Pharmacol 27: 13–18
World Health Organization (1987) Arterial hypertension: report of a WHO expert committee. WHO Technical Report Series 628. World Health Organization, Geneve
Keith NM, Wagener HP, Barker NW (1939) Some different types of essential hypertension. Their course and prognosis. Am J Med Sci 197: 332–343
Frolich JC, Wilscon TW, Sweetman BJ, Smigel M, Nies AS, Carr K, Watson ST, Oates JA (1975) Urinary prostaglandins: identification and origin. J Clin Invest 55: 763–770
Patrono C, Pugliese F, Ciabattoni G, Patrignani P, Maseri A, Chierchia S, Peskar BA, Cinotti GA, Simonetti BM, Pierucci A (1982) Evidence for a direct stimulatory effect of prostacyclin on renin release in man. J Clin Invest 69: 231–239
Patrono C, Ciabattoni G, Patrignani P, Filabozzi P, Pinca E, Satta MA, Van Dorne D, Cinotti GA, Pugliese F, Pierucci A, Simonetti BM (1983) Evidence for a renal origin of urinary thromboxane B2 in health and disease. In: Samuelsson B, Paoletti R, Ramwell P (eds) Advances in Prostaglandins, Thromboxane and Leukotriene research, vol 11. Raven Press, New York
Neri Serneri GG, Masotti G, Gensini GF, Poggesi L, Abbate R, Mannelli M (1981) Prostacyclin and thromboxane A2 formation in response to adrenergic stimulation in humans: a mechanism for local control of vascular response to sympathetic activation? Cardiovasc Res 15: 287–297
Zipser RD, Morrison A, Laffi G, Duke R (1985) Assay methods for 6-keto-prostaglandin1α in human urine: comparison of chromatography techniques with radioimmunoassay and gas chromatography-negative ion mass spectrometry. J Chromatogr 339: 1–9
La Villa G, Marra F, Laffi G, Belli B, Meacci E, Fascetti P, Gentilini P (1989) Effects of rhein on renal arachidonic acid metabolism and renal function in patients with congestive heart failure: Eur J Clin Pharmacol 37: 1–5
Gentilini P, Laffi G, Meacci E, La Villa G, Cominelli F, Pinzani M, Buzzelli G (1988) Effects of OKY 046, a thromboxane synthase inhibitor, on renal function in non-azotemic cirrhotic patients with ascites. Gastroenterology 94: 1470–1477
Meacci E, La Villa G, Laffi G, Cominelli F, Di Donato M, Dabizzi P, Albani F, Gentilini P (1987) Systemic haemodynamics, renal and platelet function during chronic propranolol administration in patients with compensated cirrhosis. Liver 7: 110–115
Richards AM, Nicholls AM, Ikram H, Webster MW, Yandle TG, Espiner EA (1985) Renal haemodynamic and hormonal effects of human α-atrial natriuretic peptide in healthy volunteers. Lancet I: 545–549
Struthers AD, Anderson JV, Causon RC, Christofides ND, Bloom SR (1985) The effect of human natriuretic peptide on urinary sodium and urinary dopamine excretion in man. J Hypertension 3: S315-S317
Anderson JV, Struthers AD, Christofides ND, Bloom SR (1986) Atrial natriuretic peptide: an endogenous factor enhancing sodium excretion in man. Clin Sci 70: 327–331
Katoh T, Sophasan S, Kurokawa K (1989) Permissive role of dopamine in renal action of ANP in volume-expanded rats. Am J Physiol 257: F300-F309
Murphy MB, Glock D, Lubbers NL, Goldberg LI (1986) Effects of atrial natriuretic factor are independent of dopamine (DAl) receptor activation (abstract). Clin Res 34: 717A
Murphy MB, Bass AS, Goldberg LI (1988) Renal effects of atrial natriuretic factor are independent of dopaminel receptors. Am J Physiol 255: F494-F499
Kastner PR, Ertel MA, Bohnke RA, Emmert LW, Burkhard TA (1987) Dopamine (DAl) receptor blockade does not inhibit the diuretic/natriuretic (D/N) effects of Ile12 5–28 atrial natriuretic peptide in rhesus monkeys (Abstract). Federation Proc 46: 1296
Petterson A, Hedner J, Hedner T (1989) Relationship between renal sympathetic activity and diuretic effects of atrial natriuretic peptide (ANP) in the rat. Acta Physiol Scand 135: 323–233
Lewis HM, Wilkins MR, Kendall MJ, Lee MR (1989) Carbidopa does not affect the renal response to atrial natriuretic factor in man. Clin Sci 77: 281–285
Kageyama S, Brown J, Causon R, O'Flynn M, Aber V (1990) DOPA decarboxylase inhibition does not influence the diuretic and natriuretic response to exogenous α-atrial natriuretic peptide in man. Eur J Clin Pharmacol 38: 223–227
Salazar FJ, Fiksen-Olsen MJ, Opgenorth TJ, Granger JP, Burnett JC Jr, Romero JC (1986) Renal effects of ANP without changes in glomerular filtration rate and blood pressure. Am J Physiol 251: F532-F536
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fronzaroli, C., La Villa, G., Strazzulla, G. et al. Renal effects of atrial natriuretic peptide during dopa-decarboxylase inhibition in patients with essential hypertension. Eur J Clin Pharmacol 44, 423–427 (1993). https://doi.org/10.1007/BF00315537
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315537